Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P21
Within normal range
vs 2Y Ago
-1.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -13.01% |
| Q3 2025 | 12.94% |
| Q2 2025 | 3.16% |
| Q1 2025 | -6.98% |
| Q4 2024 | 4.37% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | -100.00% |
| Q4 2023 | 12.00% |
| Q3 2023 | -16.00% |
| Q2 2023 | 7.92% |
| Q1 2023 | -18.25% |
| Q4 2022 | -3.89% |
| Q3 2022 | -1.09% |
| Q2 2022 | -27.27% |
| Q1 2022 | -1.06% |
| Q4 2021 | -3.35% |
| Q3 2021 | 8.96% |
| Q2 2021 | 2.94% |
| Q1 2021 | 2.52% |
| Q4 2020 | -1.39% |
| Q3 2020 | 11.92% |
| Q2 2020 | -5.52% |
| Q1 2020 | -13.93% |
| Q4 2019 | 31.42% |
| Q3 2019 | -7.53% |
| Q2 2019 | 7.79% |
| Q1 2019 | -37.79% |
| Q4 2018 | 431.13% |
| Q3 2018 | -17.23% |
| Q2 2018 | 38.94% |
| Q1 2018 | 19.25% |
| Q4 2017 | 12.14% |
| Q3 2017 | -2.27% |
| Q2 2017 | 19.30% |
| Q1 2017 | -5.79% |
| Q4 2016 | 24.27% |
| Q3 2016 | -6.91% |
| Q2 2016 | -8.60% |
| Q1 2016 | -22.63% |